TY - GEN
T1 - Adjuvant therapy for malignant melanoma-MAGE.A3 vaccines and bevacizumab
AU - Lorigan, P
N1 - Conference presentation: Joint session of The Interdisciplinary Melanoma/Skin Cancer Centres and the Melanoma Update for Primary Care Physicians, Surgeons, Oncologists, and Dermatologists, Saturday 12 November 2011.
PY - 2011
Y1 - 2011
N2 - DERMA (ADjuvant ImmunothERapy with MAGE3 in MelanomA) is a double-blind, randomized, placebo controlled phase III study of recombinant MAGE-A3+ AS15 antigen specific cancer immunotherapeutic (ASCI) in patients with MAGE.A3 positive resected stage III melanoma. MAGE-A3 is expressed on approximately 60% of melanoma specimens. This study has completed accrual of 1300 patients. The primary endpoint is disease-free survival. Additionally, the study examines the role of a molecular predictor in identifying patients likely to benefit from treatment with the MAGE.A3 vaccine +AS15. Patients received an induction phase with five vaccinations given 3-weekly followed by eight vaccinations given every 3 months. DERMA is based on the EORTC phase II study in patients with stage IV M1A disease. This identified a superior survival benefit for patients receiving the MAGE-A3 vaccine treated with the AS15 rather than the ASO2B adjuvant [HR 0.55, (95% CI, 0.28; 1.06)]. Furthermore, a genetic predictor identified a group of patients receiving MAGE-A3+ AS15 ASCI with a better overall survival [HR 0.27 (95% CI, 0.08; 0.89)]. AVAST-M (Adjuvant AVAStin Trial in High-Risk Melanoma) is a randomized multi-centred phase III study evaluating bevacizumab as an adjuvant therapy for patients with high-risk [AJCC stage IIB (T3bN0M0 & T4aN0M0), IIC (T4bN0M0) and III (TxN1-3M0)] cutaneous melanoma. Patients are randomised to received bevacizumab 7.5 mg/kg IVQ 3 weeks for 1 yr, or routine follow-up. The primary endpoint is overall survival. Thirteen hundred and twenty patients are required to show an 8% survival benefit at 5 yr. The trial will complete accrual in early 2012. The concept of the study was based on the importance of angiogenic shift in development of the metastatic process, the correlation of increased expression of vascular markers with stage and prognosis in melanoma and the positive two outcomes seen in the combination of bevacizumab with chemotherapy in a number of solid tumours.
AB - DERMA (ADjuvant ImmunothERapy with MAGE3 in MelanomA) is a double-blind, randomized, placebo controlled phase III study of recombinant MAGE-A3+ AS15 antigen specific cancer immunotherapeutic (ASCI) in patients with MAGE.A3 positive resected stage III melanoma. MAGE-A3 is expressed on approximately 60% of melanoma specimens. This study has completed accrual of 1300 patients. The primary endpoint is disease-free survival. Additionally, the study examines the role of a molecular predictor in identifying patients likely to benefit from treatment with the MAGE.A3 vaccine +AS15. Patients received an induction phase with five vaccinations given 3-weekly followed by eight vaccinations given every 3 months. DERMA is based on the EORTC phase II study in patients with stage IV M1A disease. This identified a superior survival benefit for patients receiving the MAGE-A3 vaccine treated with the AS15 rather than the ASO2B adjuvant [HR 0.55, (95% CI, 0.28; 1.06)]. Furthermore, a genetic predictor identified a group of patients receiving MAGE-A3+ AS15 ASCI with a better overall survival [HR 0.27 (95% CI, 0.08; 0.89)]. AVAST-M (Adjuvant AVAStin Trial in High-Risk Melanoma) is a randomized multi-centred phase III study evaluating bevacizumab as an adjuvant therapy for patients with high-risk [AJCC stage IIB (T3bN0M0 & T4aN0M0), IIC (T4bN0M0) and III (TxN1-3M0)] cutaneous melanoma. Patients are randomised to received bevacizumab 7.5 mg/kg IVQ 3 weeks for 1 yr, or routine follow-up. The primary endpoint is overall survival. Thirteen hundred and twenty patients are required to show an 8% survival benefit at 5 yr. The trial will complete accrual in early 2012. The concept of the study was based on the importance of angiogenic shift in development of the metastatic process, the correlation of increased expression of vascular markers with stage and prognosis in melanoma and the positive two outcomes seen in the combination of bevacizumab with chemotherapy in a number of solid tumours.
KW - melanoma adjuvant therapy human patient overall su
UR - http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/360/CN-01028360/frame.html
UR - http://www.mendeley.com/research/adjuvant-therapy-malignant-melanomamagea3-vaccines-bevacizumab
U2 - 10.1111/j.1755-148X.2011.00909.x
DO - 10.1111/j.1755-148X.2011.00909.x
M3 - Other contribution
VL - 24
T3 - Pigment cell & melanoma research
ER -
